Bank of America Begins Coverage on CeriBell (NASDAQ:CBLL)

Bank of America began coverage on shares of CeriBell (NASDAQ:CBLL) in a report published on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $32.00 price target on the stock.

A number of other research analysts have also issued reports on the company. Canaccord Genuity Group started coverage on CeriBell in a report on Tuesday. They issued a “buy” rating and a $30.00 target price on the stock. William Blair assumed coverage on shares of CeriBell in a report on Tuesday. They issued an “outperform” rating on the stock. TD Cowen started coverage on shares of CeriBell in a research note on Tuesday. They set a “buy” rating and a $31.00 price target on the stock. Finally, JPMorgan Chase & Co. began coverage on CeriBell in a research note on Tuesday. They set an “overweight” rating and a $32.00 target price for the company. Six investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, CeriBell currently has a consensus rating of “Buy” and an average target price of $31.00.

CeriBell Price Performance

Shares of CeriBell stock opened at $26.96 on Tuesday. CeriBell has a 12 month low of $23.00 and a 12 month high of $27.71.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.